Cargando…

Pilot Analysis of Late Conversion to Belatacept in Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity

BACKGROUND: Calcineurin inhibitors are associated with chronic nephrotoxicity, manifesting as interstitial fibrosis/tubular atrophy (IF/TA) and arteriolar hyalinosis. Conversion from tacrolimus to belatacept may be one strategy to preserve renal function. METHODS: We conducted a retrospective review...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Shruti, Rosales, Ivy, Wojciechowski, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954857/ https://www.ncbi.nlm.nih.gov/pubmed/29854421 http://dx.doi.org/10.1155/2018/1968029

Ejemplares similares

Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biopsy
por: Pérez-Sáez, María José, et al.
Publicado: (2018)

Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction
por: Snyder, Heather S, et al.
Publicado: (2016)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021)

Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients
por: Kirk, Allan D., et al.
Publicado: (2020)

Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
por: Terrec, Florian, et al.
Publicado: (2019)

Prevention of acute rejection after rescue with Belatacept by association of low-dose Tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction
por: Gallo, Ester, et al.
Publicado: (2020)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients
por: Letellier, Thibault, et al.
Publicado: (2022)

Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept
por: Choi, Mira, et al.
Publicado: (2020)

Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome
por: Tatapudi, Vasishta S., et al.
Publicado: (2018)

Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients
por: van der Zwan, Marieke, et al.
Publicado: (2018)

Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high‐risk cytomegalovirus serostatus kidney transplant recipients
por: Magua, Wairimu, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Conversion to belatacept after lung transplantation: Report of 10 cases
por: Brugière, Olivier, et al.
Publicado: (2023)

Systematic conversion to generic tacrolimus in stable kidney transplant recipients
por: Rosenborg, Staffan, et al.
Publicado: (2014)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept
por: Schwarz, Chloë, et al.
Publicado: (2023)

Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review
por: Kumar, Jayant, et al.
Publicado: (2021)

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial
por: Bredewold, Obbo W., et al.
Publicado: (2022)

Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients
por: Gouin, Anna, et al.
Publicado: (2020)

Biopsy-Proven Renal-Limited Thrombotic Microangiopathy in a Heart Transplant Recipient
por: Bharati, Joyita, et al.
Publicado: (2023)

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study
por: Bremer, Sara, et al.
Publicado: (2009)

Treatment of Acute Tacrolimus Toxicity with Phenytoin in Solid Organ Transplant Recipients
por: Jantz, Arin S., et al.
Publicado: (2013)

Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
por: Coscia, Lisa, et al.
Publicado: (2023)

Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
por: Wojciechowski, David, et al.
Publicado: (2012)

Converting Maintenance Kidney-Transplant Patients From Belatacept to Another Immunosuppressive Regimen: A Cautionary Tale
por: Chandran, Sindhu, et al.
Publicado: (2020)

Role of B and T Lymphocyte Attenuator in Renal Transplant Recipients with Biopsy-Proven Acute Rejection
por: Wang, Zijie, et al.
Publicado: (2018)

Belatacept in renal transplantation—quo vadis?
por: Westhoff, Timm H.
Publicado: (2016)

Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms
por: de Graav, Gretchen N., et al.
Publicado: (2018)

Immunosuppression with generic tacrolimus in liver and kidney transplantation—systematic review and meta‐analysis on biopsy‐proven acute rejection and bioequivalence
por: Kahn, Judith, et al.
Publicado: (2020)

Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial
por: Plischke, Max, et al.
Publicado: (2015)

Phase I study of single‐dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients
por: Moudgil, Asha, et al.
Publicado: (2019)

Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate
por: Belliere, Julie, et al.
Publicado: (2014)

Cellular and molecular immune profiles in renal transplant recipients after conversion from Tacrolimus to Sirolimus
por: Gallon, Lorenzo, et al.
Publicado: (2014)

Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
por: Kim, Jong Man, et al.
Publicado: (2016)

Torque Teno Virus for Risk Stratification of Acute Biopsy-Proven Alloreactivity in Kidney Transplant Recipients
por: Strassl, Robert, et al.
Publicado: (2019)

Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants
por: Kumar, Dhiren, et al.
Publicado: (2017)

Tacrolimus Toxicity due to Biliary Obstruction in a Combined Kidney and Liver Transplant Recipient
por: Chan, Samuel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gcarmr33m99qe29g360k2avhri